New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:06 EDTEXASExact Sciences announces DeeP-C study results published
Exact Sciences announced that results from its DeeP-C clinical study have been published online in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3 print issue. The company said, "In our clinical study, the data show that Cologuard, the multi-target stool-based DNA test, is highly sensitive in detecting colorectal cancer and higher risk pre-cancerous polyps in a large, diverse average-risk patient population and has the potential to be an important screening tool.” The Exact Sciences Cologuard screening test is an investigational device currently under review by the U.S. Food and Drug Administration and is not available for sale in the U.S. The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 13, 2015
08:01 EDTEXASExact Sciences says Cologuard receives coverage by several health plans in Q1
Since the start of 2015, several insurers began covering Cologuard as a noninvasive colon cancer screening test. In addition to several smaller regional providers, insurance plans covering the test now include: Anthem Blue Cross and Blue Shield, a leading national health plan with more than 37 million members across 14 states, Tufts Health Plan, with more than 1 million members across Massachusetts and Rhode Island and ranked the number one health plan for quality in the country for its Commercial plans and its Medicaid plans, CareFirst BlueCross BlueShield PPO, with 2.3 million eligible members across Maryland, District of Columbia and Northern Virginia, Excellus BCBS WNY, with more than 1.4 million members across Western New York and Dean Health Plan, insuring more than 272,037 members across Central Wisconsin.
April 8, 2015
07:53 EDTEXASExact Sciences survey results positive, says JMP Securities
After surveying 102 high-FIT/FOBT prescribing primary care and ob/gyn physicians who have been prescribing ColoGuard for at least four months, JMP Securities says that utilization of Exact Sciences' ColoGuard is increasing at a rapid pace. The firm adds that doctors are becoming more optimistic regarding the potential long-term penetration of ColoGuard into the market. The firm reiterates a $27 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use